Page last updated: 2024-12-08

a 76928

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

A 76928: a diol with C2-symmetry [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID446148
CHEMBL ID406493
SCHEMBL ID6449595
MeSH IDM0251562

Synonyms (15)

Synonym
jmc51852 inhibitor pp
(2s)-n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[(2s)-3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]-3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanamide
bdbm198
a-76928
a 76928
2,5-(s,s)-bis(2-pyridylmethoxyvalyl)-1,6-diphenyl-3,4-(s,s)-dihydroxyhexane
(2s)-n-[(1s,2s,3s,4s)-1-benzyl-2,3-dihydroxy-4-[[(2s)-3-methyl-2-[[methyl(2-pyridylmethyl)carbamoyl]amino]butanoyl]amino]-5-phenyl-pentyl]-3-methyl-2-[[methyl(2-pyridylmethyl)carbamoyl]amino]butanamide
n-{1-benzyl-(2s,3s)-2,3-dihydroxy-4-[3-methyl-2-(3-methyl-3-pyridin-2-ylmethyl-ureido)-butyrylamino]-5-phenyl-pentyl}-3-methyl-2-(3-methyl-3-pyridin-2-ylmethyl-ureido)-butyramide
A79 ,
1HVK
(2s)-n-[(2s,3s,4s,5s)-3,4-dihydroxy-5-[[(2s)-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]-3-methyl-2-[[methyl(pyridin-2-ylmethyl)carbamoyl]amino]butanamide
CHEMBL406493
SCHEMBL6449595
(2s,2's)-n,n'-[(2s,3s,4s,5s)-3,4-dihydroxy-1,6-diphenylhexane-2,5-diyl]bis(3-methyl-2-{[methyl(pyridin-2-ylmethyl)carbamoyl]amino}butanamide) (non-preferred name)
Q27457144
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RKi0.00510.00000.51449.0000AID1798005
Protease Human immunodeficiency virus 1Ki0.00530.00000.04433.1000AID160308; AID321469
Protease Human immunodeficiency virus 1IC50 (µMol)0.01510.00000.81769.8500AID449367
Protease Human immunodeficiency virus 1Ki0.00130.00000.02841.1000AID321468
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1EC50 (µMol)0.28000.06000.13400.2800AID161889
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID321470Ratio of Ki for HIV1 protease V82A mutant to Ki for wild type HIV1 protease2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
AID20931Compound was evaluated for the solubility at the pH 7.41994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID321468Binding affinity to HIV1 protease2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
AID161889Effective concentration of compound for inhibition of HIV 1 protease was determined1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID321469Binding affinity to HIV1 protease V82A mutant2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
AID160769Affinity for HIV Protease2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID449367Inhibition of HIV1 protease expressed in Escherichia coli K12 assessed as inhibition of enzyme activity2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
AID160308Compound was evaluated for the inhibitory activity against HIV-1 protease1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Application of the three-dimensional structures of protein target molecules in structure-based drug design.
AID1798005Protease Inhibition Assay from Article 10.1021/jm701170f: \\Design, Synthesis, Evaluation, and Crystallographic-Based Structural Studies of HIV-1 Protease Inhibitors with Reduced Response to the V82A Mutation.\\2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's3 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.41 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]